ACHL Achilles Therapeutics
- 0.890
- -0.050-5.35%
Achilles Therapeutics News
Achilles Therapeutics: Promising Q1 2024 Results
Achilles Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Achilles Therapeutics Showcases Solid Q1 2024 Financials
Press Release: Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights -- Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and me
Achilles Therapeutics 1Q Loss $12.3M >ACHL
Achilles Therapeutics 1Q Loss $12.3M >ACHL
Achilles Therapeutics 1Q Loss/Shr 30c >ACHL
Achilles Therapeutics 1Q Loss/Shr 30c >ACHL
Achilles Therapeutics Is Maintained at Buy by Chardan Capital
Achilles Therapeutics Is Maintained at Buy by Chardan Capital
Achilles Therapeutics Price Target Cut to $6.00/Share From $11.00 by Chardan Capital
Achilles Therapeutics Price Target Cut to $6.00/Share From $11.00 by Chardan Capital
Achilles Therapeutics Cut to Neutral From Overweight by Piper Sandler
Achilles Therapeutics Cut to Neutral From Overweight by Piper Sandler
Piper Sandler Downgrades Achilles Therapeutics to Neutral, Lowers Price Target to $2
Piper Sandler analyst Joseph Catanzaro downgrades Achilles Therapeutics (NASDAQ:ACHL) from Overweight to Neutral and lowers the price target from $8 to $2.
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of STAAR Surgical Company (NASDAQ:STAA) rose sharply during Thursday's session after the company issued strong preliminary first-quarter net sales guidance. STAAR Surgical shares jumped 13.3%
BRNS, UPC and KWE Among Mid-day Movers
Achilles Therapeutics GAAP EPS of -$0.46 Misses by $0.32
Nasdaq Surges 1%; ConAgra Brands Posts Upbeat Earnings
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 150 points on Thursday. The Dow traded up 0.49% to 39,319.03 while the NASDAQ rose 1% to 16,4340. The S&P
ARCA Biopharma, Achilles Therapeutics, MSP Recovery Among Healthcare Movers
EC, ABAT and BORR Among Pre-market Losers
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersTevogen Bio Holdings (NASDAQ:TVGN) stock rose 85.5% to $4.86 during Thursday's pre-market session. The market value of their outstanding shares is at $800.0 million. Candel Therapeutics (NASDAQ
Achilles Therapeutics Q4 EPS $(0.46) May Not Be Comparable To $(0.14) Estimate, Cash Position Of $131.5M Supports Operations Through 2025
Achilles Therapeutics (NASDAQ:ACHL) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.14) by 228.57 percent. This is a 24.59 percent increase over losse
Achilles Therapeutics Provides Interim Phase 1/2a Update on Clonal Neoantigen Reactive T Cells In Advanced NSCLC And Melanoma Including First Patients Dosed With Enhanced Host Conditioning
Improved VELOS manufacturing process delivering higher cNeT doses.Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024.First three patients do
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid
Analysis
Price Target
No Data
